Diverse monoclonal antibodies against the CA 19-9 antigen show variation in binding specificity with consequences for clinical interpretation

Proteomics

Volumn 12, Issue 13, 2012, Pages 2212-2220

  Partyka, Katie ^a   Maupin, Kevin A ^a   Brand, Randall E ^b   Haab, Brian B ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Antibody microarrays; Biomarkers; Biomedicine; Cancer; Carbohydrates; Glycomics

Indexed keywords

BIOLOGICAL MARKER; CA 19-9 ANTIGEN; EPITOPE; GLYCAN; MONOCLONAL ANTIBODY; SIALYL LEWIS X ANTIGEN;

ANTIBODY BLOOD LEVEL; ANTIBODY STRUCTURE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CANCER DIAGNOSIS; CANCER PATIENT; COHORT ANALYSIS; CONTROLLED STUDY; HUMAN; PANCREAS CANCER; PANCREATITIS; PRIORITY JOURNAL; PROTEIN MODIFICATION;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CA-19-9 ANTIGEN; CARBOHYDRATE SEQUENCE; COHORT STUDIES; HUMANS; MOLECULAR SEQUENCE DATA; PANCREATIC NEOPLASMS; POLYSACCHARIDES; PROTEIN ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84864005063     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201100676     Document Type: Article

References (39)

1. Goonetilleke, K. S., Siriwardena, A. K., Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur. J. Surg. Oncol. 2007, 33, 266-270.
2. Molina, V., Visa, L., Conill, C., Navarro, S. et al., CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer. Tumour Biol. 2012, 33, 799-807.
3. Tempero, M. A., Uchida, E., Takasaki, H., Burnett, D. A. et al., Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987, 47, 5501-5503.
4. Barton, J. G., Bois, J. P., Sarr, M. G., Wood, C. M. et al., Predictive and prognostic value of CA 19-9 in resected pancreatic adenocarcinoma. J. Gastrointest. Surg. 2009, 13, 2050-2058.
5. Ishii, H., Okada, S., Sato, T., Wakasugi, H. et al., CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer. Hepato-gastroenterology 1997, 44, 279-283.
6. Micke, O., Bruns, F., Schafer, U., Kurowski, R. et al., CA 19-9 in the therapy monitoring and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy. Anticancer Res. 2003, 23, 835-840.
7. Hess, V., Glimelius, B., Grawe, P., Dietrich, D. et al., CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol. 2008, 9, 132-138.
8. Boeck, S., Haas, M., Laubender, R. P., Kullmann, F. et al., Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer. Clin. Cancer Res. 2010, 16, 986-994.
9. Varki, A., Cummings, R., Esko, J., Freeze, H. et al., Essentials of Glycobiology, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 2009.
10. Lahdenne, P., Pitkanen, S., Rajantie, J., Kuusela, P. et al., Tumor markers CA 125 and CA 19-9 in cord blood and during infancy: developmental changes and use in pediatric germ cell tumors. Pediatr. Res. 1995, 38, 797-801.
11. Magnani, J. L., Steplewski, Z., Koprowski, H., Ginsburg, V., Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res. 1983, 43, 5489-5492.
12. Kalthoff, H., Kreiker, C., Schmiegel, W. H., Greten, H. et al., Characterization of CA 19-9 bearing mucins as physiological exocrine pancreatic secretion products. Cancer Res. 1986, 46, 3605-3607.
13. Yue, T., Partyka, K., Maupin, K. A., Hurley, M. et al., Identification of blood-protein carriers of the CA 19-9 antigen and characterization of prevalence in pancreatic diseases. Proteomics 2011, 11, 3665-3674.
14. Yue, T., Goldstein, I. J., Hollingsworth, M. A., Kaul, K. et al., The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays. Mol. Cell. Proteomics 2009, 8, 1697-1707.
15. Manimala, J. C., Roach, T. A., Li, Z., Gildersleeve, J. C., High-throughput carbohydrate microarray profiling of 27 antibodies demonstrates widespread specificity problems. Glycobiology 2007, 17, 17C-23C.
16. Alper, J., Glycobiology. Turning sweet on cancer. Science 2003, 301, 159-160.
17. Dennis, J. W., Granovsky, M., Warren, C. E., Glycoprotein glycosylation and cancer progression. Biochim. Biophys. Acta 1999, 1473, 21-34.
18. Yue, T., Haab, B. B., Microarrays in glycoproteomics research. Clin. Lab. Med. 2009, 29, 15-29.
19. Forrester, S., Kuick, R., Hung, K. E., Kucherlapati, R. et al., Low-volume, high-throughput sandwich immunoassays for profiling plasma proteins in mice: identification of early-stage systemic inflammation in a mouse model of intestinal cancer. Mol. Oncol. 2007, 1, 216-225.
20. Drickamer, K., Taylor, M. E., Glycan arrays for functional glycomics. Genome Boil. 2002, 3, REVIEWS1034.
21. Blixt, O., Head, S., Mondala, T., Scanlan, C. et al., Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc. Natl. Acad. Sci. U. S.A. 2004, 101, 17033-17038.
22. Haab, B. B., Yue, T., High-throughput studies of protein glycoforms using antibody-lectin sandwich arrays. Methods Mol. Biol. 2011, 785, 223-236.
23. Porter, A., Yue, T., Heeringa, L., Day, S. et al., A motif-based analysis of glycan array data to determine the specificities of glycan-binding proteins. Glycobiology 2010, 20, 369-380.
24. Tangvoranuntakul, P., Gagneux, P., Diaz, S., Bardor, M. et al., Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc. Natl. Acad. Sci U.S.A. 2003, 100, 12045-12050.
25. Inoue, S., Sato, C., Kitajima, K., Extensive enrichment of N-glycolylneuraminic acid in extracellular sialoglycoproteins abundantly synthesized and secreted by human cancer cells. Glycobiology 2010, 20, 752-762.
26. Padler-Karavani, V., Hurtado-Ziola, N., Pu, M., Yu, H. et al., Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer. Cancer Res. 2011, 71, 3352-3363.
27. Cakir, B., Pankow, J. S., Salomaa, V., Couper, D. et al., Distribution of Lewis (FUT3)genotype and allele: frequencies in a biethnic United States population. Ann. Hematol. 2002, 81, 558-565.
28. Orntoft, T. F., Vestergaard, E. M., Holmes, E., Jakobsen, J. S. et al., Influence of Lewis alpha1-3/4-L-fucosyltransferase (FUT3) gene mutations on enzyme activity, erythrocyte phenotyping, and circulating tumor marker sialyl-Lewis a levels. J. Biol. Chem. 1996, 271, 32260-32268.
29. Narimatsu, H., Iwasaki, H., Nakayama, F., Ikehara, Y. et al., Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients. Cancer Res. 1998, 58, 512-518.
30. Kawa, S., Oguchi, H., Kobayashi, T., Tokoo, M. et al., Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype. Br. J. Cancer 1991, 64, 899-902.
31. Takasaki, H., Uchida, E., Tempero, M. A., Burnett, D. A. et al., Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patients. Cancer Res. 1988, 48, 1435-1438.
32. Meany, D. L., Chan, D. W., Aberrant glycosylation associated with enzymes as cancer biomarkers. Clin Proteomics 2011, 8, 7.
33. Sessa, F., Bonato, M., Frigerio, B., Capella, C. et al., Ductal cancers of the pancreas frequently express markers of gastrointestinal epithelial cells. Gastroenterology 1990, 98, 1655-1665.
34. Malykh, Y. N., Schauer, R., Shaw, L., N-Glycolylneuraminic acid in human tumours. Biochimie 2001, 83, 623-634.
35. Yamamoto, F., Clausen, H., White, T., Marken, J. et al., Molecular genetic basis of the histo-blood group ABO system. Nature 1990, 345, 229-233.
36. Elmgren, A., Mollicone, R., Costache, M., Borjeson, C. et al., Significance of individual point mutations, T202C and C314T, in the human Lewis (FUT3) gene for expression of Lewis antigens by the human alpha(1, 3/1, 4)-fucosyltransferase, Fuc-TIII. J. Biol. Chem. 1997, 272, 21994-21998.
37. Yang, Z., Harris, L. E., Palmer-Toy, D. E., Hancock, W. S., Multilectin affinity chromatography for characterization of multiple glycoprotein biomarker candidates in serum from breast cancer patients. Clin. Chem. 2006, 52, 1897-1905.
38. Song, X., Lasanajak, Y., Xia, B., Heimburg-Molinaro, J. et al., Shotgun glycomics: a microarray strategy for functional glycomics. Nat. Methods 2011, 8, 85-90.
39. Zhao, J., Qiu, W., Simeone, D. M., Lubman, D. M., N-linked glycosylation profiling of pancreatic cancer serum using capillary liquid phase separation coupled with mass spectrometric analysis. J. Proteome Res. 2007, 6, 1126-1138.